Last reviewed · How we verify
Irbesartan Oral Tablet
Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes and hypertension.
At a glance
| Generic name | Irbesartan Oral Tablet |
|---|---|
| Sponsor | University of Southern Denmark |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Irbesartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation and reduces sodium and water retention, thereby decreasing blood pressure and reducing cardiac workload. This mechanism also provides renal protection in patients with hypertension and diabetes.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes and hypertension
Common side effects
- Dizziness
- Fatigue
- Musculoskeletal pain
- Hyperkalemia
- Elevated creatinine
Key clinical trials
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (PHASE3)
- Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU. (PHASE3)
- Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (PHASE3)
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PHASE3)
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy (PHASE2)
- Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE) (PHASE3)
- Low-dose Quadruple Combination Therapy in Patients With Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irbesartan Oral Tablet CI brief — competitive landscape report
- Irbesartan Oral Tablet updates RSS · CI watch RSS
- University of Southern Denmark portfolio CI